Morgan Stanley’s NeuroSense Therapeutics NRSN Stock Holding History

Morgan Stanley’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-66,400	Closed	-$83K	–	8387
2025 Q3	$83K	Sell	66,400 -13,500	-17%	-$19.8K	﹤0.01%	6236
2025 Q2	$151K	Buy	79,900 +29,399	+58%	+$42.6K	﹤0.01%	5961
2025 Q1	$47K	Sell	50,501 -52,080	-51%	-$57.6K	﹤0.01%	6292
2024 Q4	$123K	Buy	+102,581	New	+$118K	﹤0.01%	5975
2024 Q3	–	Sell	-1,500	Closed	-$1.68K	–	7997
2024 Q2	$1.68K	Hold	1,500	–	–	﹤0.01%	7089
2024 Q1	$2.73K	Sell	1,500 -1,500	-50%	-$2.02K	﹤0.01%	7019
2023 Q4	$2.36K	Buy	+3,000	New	+$1.99K	﹤0.01%	7117
2023 Q1	–	Sell	-4	Closed	-$5	–	7796
2022 Q4	$5	Hold	4	–	–	﹤0.01%	7832
2022 Q3	$0	Buy	+4	New	+$8	﹤0.01%	7819

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Morgan Stanley's NRSN Position: Q4 2025 in Review

Morgan Stanley sold out of NeuroSense Therapeutics (NRSN) in Q4 2025, closing a stake of 66,400 shares — an estimated $83K sold.

Morgan Stanley first reported a position in NRSN in Q3 2022 and held it in 9 quarters. The position peaked at $151K in Q2 2025. 13 funds tracked by Wall St. Rank hold NRSN as of Q4 2025.

Morgan Stanley reported no remaining NeuroSense Therapeutics position as of Q4 2025 after selling out during the quarter.
Morgan Stanley sold 66,400 NeuroSense Therapeutics shares in Q4 2025, an estimated $83K.
Morgan Stanley first reported a position in NeuroSense Therapeutics in Q3 2022 and held it in 9 quarters.
Morgan Stanley's NeuroSense Therapeutics position peaked at $151K in Q2 2025.
13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.